Tofranil is a member of the tricyclic family of psychotropic medications designed to treat serious disorders that cause harm to the patient. Behaviors such as cutting, self burning, self mutilation, and hair pulling are all disorders that can benefit from Tofranil. It is most commonly prescribed to treat symptoms of severe depression.
It is likely that during the first twelve weeks of taking Tofranil, or its generic form, imipramine, that suicidal ideation may very well increase. The prescribing physician should have regular visitation with the patient as he is adjusting to prevent a suicide attempt.
Tofranil can be very dangerous in the hands of a suicidal patient, and it should be made very clear at the onset of treatment that these thoughts and feelings can be triggered by the medication and does not necessarily mean a worsening of the depression and the patient should report these symptoms immediately.
Tofranil can cause serious complications in patients with heart disease, diabetes, kidney or liver disease, bi-polar disorder, eating disorders, thyroid problems, urinary difficulties, glaucoma, or adrenal gland tumors. Patients with any of these diseases should not be prescribed Tofranil.
There is a serious risk of drug interaction associated with imipramine. It is likely to cause serious illness or death if they interact with any other anti-psychotic or psychotropic medications. Over the counter cough and cold remedies and allergy medications are potentially dangerous. Heart rhythm regulators, cimetidine, clonidine, guanethidine, and methylphenidate can all react with serious consequences.
If a patient begins to experience heart attack or stroke symptoms, shortness of breath, swelling, rapid weight gain or confusion with convulsions, restlessness of the face and jaw and neck, extreme thirst, skin rash, or muscle weakness, they need to be instructed to call their prescribing physician immediately. These are signs of serious reactions.
Nausea, stomach pain with diarrhea or constipation, dry mouth with altered taste, weight changes or a sudden clumsiness, insomnia and nightmares or night terrors, dizziness, drowsiness, or anxiety, blurry vision with hearing impairment, breast swelling, or sexual dysfunction are all common side effects. Most patients do not feel the side effects are bad enough to stop taking Tofranil and that the benefits are worth the discomfort. Most patients are not prescribed Tofranil indefinitely as talking therapy and other therapies are combined with drug therapy to create a better outlook on life.
Though Tofranil is part of a family of very heavy and serious psychotropic medications, it is one of the more mundane of the group. While the potential side effects and drug interactions are quite dangerous, the list of side effects and potential interactions are not quite as intensive. Great care is needed in caring for patients with severe disorders as they may not always be able to recognize the severity of their own side effects. Independent patients run the risk of further complications much more so than patients that are institutionalized. Educating patients is vital for their safety, even when it is difficult to do so.
Imipramine hydrochloride is a member of the dibenzazepine group of compounds. It is designated 5-[3-( Dimethylamino)propyl]-10,11- ihydro-5H-dibenz [b,1-azepine] Monohydrochloride. Its molecular weight is 316.87 and its molecular formula is C19H25N2Cl. Imipramine hydrochloride is a white to off-white, odorless, or practically odorless crystalline powder. It is freely soluble in water and in alcohol, soluble in acetone, and insoluble in ether and in benzene.
Tofranil has the following structural formula: